Group 1 - Haitai Development plans to acquire controlling stake in Zhixueyun through cash, which may constitute a major asset restructuring [3] - Shutaishen's product STSP-0601 has been included in the priority review list by the National Medical Products Administration, entering the expedited approval process [4] - Yuyin Co. confirmed no undisclosed significant matters despite stock price fluctuations exceeding 20% over three trading days [5] Group 2 - ST Four Seasons announced the resignation of three vice presidents due to personal reasons [6] - Wanda Film is set to launch a shareholder reward program, offering discounted movie vouchers and exclusive purchase options for shareholders [7] - Huamai Technology reported normal business operations focused on communication infrastructure, with no undisclosed significant information [8] Group 3 - Cuiwei Co. is currently experiencing losses in its main business due to market conditions and operational changes [9] - Dongfang Yuhong has received government subsidies totaling 11.3344 million yuan, accounting for 10.48% of the audited net profit for 2024 [10] Group 4 - Wen's Co. reported a 14.23% year-on-year increase in pig sales revenue for May, with total sales of 3.1554 million pigs generating 5.323 billion yuan [12] - Wentaike plans to reduce its stake by up to 3% through block trades and centralized bidding, amounting to 37.3374 million shares [14] - Debang Technology has reduced its shareholding by 1% through block trades, now holding 16.83% of the company [15] Group 5 - Lanjian Intelligent plans to repurchase shares worth 10 to 20 million yuan at a maximum price of 41.88 yuan per share [17] - Chengdi Xiangjiang's subsidiary has won a bid for a 440 million yuan project with China Mobile for data center power system construction [19]

5、纳入优先审评品种名单日期：2025 年 06 月 05 日； 证券代码：300204 证券简称：舒泰神 公告编号：2025-040 舒泰神（北京）生物制药股份有限公司 关于注射用 STSP-0601 纳入优先审评程序的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 舒泰神（北京）生物制药股份有限公司（以下简称"舒泰神"或"公司"） 子公司江苏贝捷泰生物科技有限公司（以下简称"贝捷泰"）的产品注射用 STSP-0601 于 2025 年 05 月 26 日被国家药品监督管理局药品审评中心纳入拟优 先审评品种公示名单；公示期满后，根据国家药品监督管理局药品审评中心网站 信息公开显示，于 2025 年 06 月 05 日纳入优先审评品种名单，正式进入药品上 市许可优先审评审批程序。现将相关情况公告如下： 一、药品基本情况 1、药品名称：注射用 STSP-0601； 2、申请人：江苏贝捷泰生物科技有限公司； 3、申请日期：2025 年 05 月 23 日； 4、公示日期：2025 年 05 月 26 日； 6、受理号：CXSS2500057 7、优先审评理由 ...

Core Viewpoint - The innovative drug sector has become a focal point in the A-share market, with Shuyou Shen (300204.SZ) emerging as a standout performer, experiencing significant stock price increases despite ongoing operational challenges [1][5]. Stock Performance - On June 4, Shuyou Shen opened high but closed at 30.79 CNY per share, down 3.18% from the previous day. The stock price surged from 11.04 CNY to 31.80 CNY between May 20 and June 3, marking a 188.04% increase over 10 trading days. From a low of 5.90 CNY on April 9, the stock has risen by 438.98% [2][11]. - The company's market capitalization increased by approximately 12.4 billion CNY due to the stock price surge [15]. - Institutional investors played a significant role in the stock's rise, with substantial buying activity noted on multiple trading days [13][14]. Financial Performance - Despite the stock price increase, Shuyou Shen's operational performance remains under pressure, with a 33.45% year-on-year decline in revenue for Q1. The net profit attributable to shareholders was -2.34 million CNY, although this represented a 38.05% reduction in losses compared to the previous year [2][19]. - The company has reported cumulative losses exceeding 1 billion CNY over five consecutive years from 2020 to 2024 [3][19]. - In 2024, the company’s revenue from its main products, Shutaqing and Sutai Sheng, declined, with sales of Shutaqing at 1.79 billion CNY (down 8.20%) and Sutai Sheng at 1.34 billion CNY (down 17.30%) [19]. Research and Development - Shuyou Shen's R&D investment dropped significantly to 162 million CNY in 2024, a decrease of 63.84% year-on-year [4][20]. - The company has reduced its R&D personnel by 14.75%, with R&D staff now comprising 21.14% of the total workforce [20]. - Despite the decline in R&D spending, the company has multiple I-class innovative biological drugs in clinical trials and is focused on advancing projects in areas such as neurological diseases and infectious diseases [20].

Summary of the Conference Call for Shuyou Shen Company Overview - Shuyou Shen focuses on infectious diseases, respiratory and critical care, autoimmune diseases, and neurological disorders [2][6] - The company has faced revenue pressure due to declining sales of its main products, Sutai Sheng and Shuyou Qing, but has a rich pipeline of innovative products that present growth potential [2][6] Key Products and Market Potential - **Bomeipide Enzyme Alpha**: A new therapy for hemophilia, showing superior hemostatic efficiency, safety, and onset speed compared to existing therapies. It is expected to become a best-in-class option [2][7][9] - Clinical data indicates a hemostatic rate and onset speed better than existing treatments [2][9] - Anticipated peak sales could exceed 2 billion RMB, with its market application already accepted [2][9] - **C5A Pathway Drugs (001 and 1,002)**: Targeting ANCA-associated vasculitis (AAV) and acute respiratory distress syndrome (ARDS) [2][5][10] - 1,002 is an upgraded version of 001, with promising clinical trial progress [2][5] - The ARDS market is significant, with approximately 3 million new patients annually and high mortality rates [4][16] - The global market for ARDS treatments is largely unmet, presenting a blue ocean opportunity [4][16] Financial Performance and R&D Progress - The company has seen a decline in revenue since 2022 due to decreased sales of existing products and increased R&D expenses [6] - Despite financial pressures, the extensive R&D pipeline, including Bomeipide Enzyme Alpha and C5A pathway drugs, is expected to drive future growth [6][17] Competitive Landscape - The global hemophilia treatment market is approximately 30 billion RMB, with major competitors including recombinant factor VII, PCC, and emicizumab [3][8] - Bomeipide Enzyme Alpha is positioned as a first-in-class product with a unique mechanism, potentially capturing a significant market share due to its advantages over existing therapies [3][9][12] Commercialization Strategies - Bomeipide Enzyme Alpha's commercialization strategy may involve high pricing to target reimbursable patients or competitive pricing to expand market share [4][12] - The overseas market for hemophilia treatments is estimated at nearly 3 billion USD, with potential for market share capture through licensing [12][14] Clinical Trial Insights - The clinical trial data for 1,002 in ARDS has shown excellent results, indicating a strong potential for market entry [5][15] - The company is also exploring multiple indications for its products, enhancing its R&D pipeline diversity [17] Investor Concerns - Investors are particularly interested in the development of 1,002 and its potential patient population size, with expectations that it will serve a broader range of patients than initially thought [18][19] Conclusion - Shuyou Shen is positioned in a promising market with innovative products that address significant unmet medical needs. The company's strategic focus on R&D and potential market capture strategies could lead to substantial growth in the coming years [2][4][6]

Core Viewpoint - Aoke Co., Ltd. collaborates with Shutai Shen to provide pharmaceutical excipient polyethylene glycol products [1] Group 1 - Aoke Co., Ltd. stated on its interactive platform that Shutai Shen (Beijing) Biopharmaceutical Co., Ltd. is a downstream customer of its subsidiary Aoke Pharmaceutical [1] - Shutai Shen primarily purchases polyethylene glycol products from Aoke Pharmaceutical [1]

Core Viewpoint - The innovative drug sector in Hong Kong and A-shares has experienced significant growth, with companies like Shuyitai (300204.SZ) seeing stock price increases of over 188% from May 20 to June 3, before a subsequent correction on June 4 [1][2]. Group 1: Market Performance - The innovative drug sector has shown strong performance this year, with the Hong Kong biopharmaceutical B-class stock index rising over 80% and the innovative drug concept index increasing by over 40%. A-share innovative drug concepts have also risen by more than 20% [2]. - Recent favorable news, including multiple innovative drug approvals in May and a record $1.25 billion upfront payment for a licensing agreement between Sanofi (01530.HK) and Pfizer (PFE.US), has further stimulated the sector [2]. Group 2: Company-Specific Developments - Shuyitai has received a significant boost from its subsidiary Beijitai, which received a notice from the National Medical Products Administration regarding the conditional approval for the injection STSP-0601, aimed at treating bleeding in adult patients with hemophilia A or B [3]. - Preliminary results from the Ib/II clinical trial of STSA-1002 for acute respiratory distress syndrome (ARDS) indicate good safety and tolerability [3]. - Despite having several products on the market, Shuyitai's revenue has been declining, primarily due to decreasing sales of its main products, leading to continuous net losses [3]. Group 3: Investment Outlook - Analysts remain optimistic about the innovative drug sector, with firms like Zhongtai Securities highlighting the increasing global competitiveness of domestic innovative drugs and the potential for significant market revaluation [5]. - The upcoming national medical insurance negotiations are seen as a critical event, with successful drug approvals expected to accelerate market penetration [5]. - The Hong Kong innovative drug sector is noted for its higher elasticity in valuation compared to A-shares, benefiting from greater research and development expenditure and overseas revenue [6].

重要新闻 1. 国务院：政府部门应当科学合理确定政务数据共享属性，不得通过擅自增设条件等方式阻碍、影响政 务数据共享 李强签署国务院令，公布《政务数据共享条例》。条例提到，政府部门应当科学合理确定政务数据共享 属性，不得通过擅自增设条件等方式阻碍、影响政务数据共享。对属于有条件共享类的政务数据，政府 部门应当在政务数据目录中列明共享范围、使用用途等共享使用条件。对属于不予共享类的政务数据， 政府部门应当在政务数据目录中列明理由，并明确相应的法律、行政法规以及国务院决定依据。（新华 社） 2. 商务部等五部门组织开展2025年新能源汽车下乡活动，特斯拉Model 3、Model Y车型在列 工业和信息化部、国家发展改革委、农业农村部、商务部、国家能源局组织开展2025年新能源汽车下乡 活动。选取一批新能源汽车推广比例不高、市场潜力较大的典型县域城市，举行若干场专场活动；以此 为中心辐射周边乡镇，结合地区特点开展若干场特色活动。与县域充换电设施补短板试点、智能网联汽 车"车路云一体化"试点等工作形成协同效应，推动优质资源向乡村地区倾斜。其中，特斯拉Model 3、 Model Y车型在列。 3. 商务部：希望欧方 ...

化学制药板块短线走低，华纳药厂跌超9%，天宇股份（300702）、舒泰神（300204）、多瑞医药 （301075）、海创药业等跟跌。 ...

Policy Developments - The State Administration for Market Regulation announced ten typical cases of illegal advertising, with multiple cases involving the medical field, including one case related to medical device advertising and two cases concerning illegal drug advertising [2] - As of the end of April, a total of 11,459 illegal advertising cases were investigated, resulting in fines totaling 88.309 million yuan [2] Drug and Device Approvals - Shuyou Shen announced that its subsidiary received a notice from the National Medical Products Administration regarding the conditional listing application for "STSP-0601," a drug aimed at promoting rapid hemostasis for adult patients with hemophilia A or B [4] - Lepu Medical received registration approval from the NMPA for its self-developed polylactic acid facial filler, known as "童颜针," marking a significant milestone in the dermatology field [5] Capital Market Activities - Baiyang Pharmaceutical announced the release of 5.3 million shares from pledge by its controlling shareholder, representing 1.44% of the shares held by the shareholder and 1.01% of the company's total share capital [7] - Jincheng Pharmaceutical provided a guarantee of 5 million yuan for its wholly-owned subsidiary, Shandong Jincheng Biological Pharmaceutical Co., Ltd. [8] Industry Developments - AstraZeneca announced significant progress in the treatment of EGFR mutation-positive non-small cell lung cancer with MET amplification, with interim results from the SACHI Phase III study to be presented at the ASCO annual meeting [10][11] - Yuheng Pharmaceutical signed a market promotion service agreement with Eisai (China) Pharmaceutical for "Mikobao," which will enhance Yuheng's product pipeline and increase revenue [12] - New Scene Intelligence authorized BeiGene to develop universal cell therapy drugs based on a specific TCR molecule, with potential milestone payments and revenue sharing [13] - Buchang Pharmaceutical withdrew its clinical trial application for a rabies vaccine, indicating the need for further research before resubmission [14] Public Opinion Alerts - Huaxi Biological responded to recent controversies regarding recombinant collagen, emphasizing the importance of product quality over naming conventions [16] - Kangning Jerey announced a share transfer agreement involving 14.6 million shares, amounting to 117 million HKD [17]

各位老铁，这里是帮主郑重的收评时间。今天这市场啊，就像端午节包粽子——外面看着热闹，里头藏着门道。沪指涨了0.43%，深成指和创业板指也跟着 回暖，但仔细看，近3400只个股上涨的背后，资金明显在玩"抓大放小"的游戏。咱们今天就拆解拆解，这反弹里到底藏着啥玄机。 先说指数反弹的"底气"从哪来 今天市场能反弹，跟政策预期升温脱不了干系。最近市场对稳增长政策的期待越来越强，加上外资回流的迹象，让不少观望资金试探性进场。不过成交量只 放量了4个亿，说明大家还是有点犹豫，就像煮粽子时火候不够，米粒还没完全开花。这时候得盯紧北向资金的动向，它们要是持续加仓，反弹才有持续 性。 创新药板块爆发：政策松绑+研发提速的双击 创新药今天集体嗨了，舒泰神、海南海药这些票涨停，可不是偶然。去年开始，创新药审批流程大幅缩短，加上老龄化带来的刚性需求，这个板块就像压紧 的弹簧。我跟药企研发总监聊过，现在一款创新药从立项到上市周期比三年前快了30%，这就好比做菜从慢炖变成高压锅，效率上去了，利润空间自然就打 开了。不过要提醒老铁们，别光看涨停就追高，得看企业真正的研发管线厚度，有些票可能只是蹭概念。 银行股稳如泰山：高股息成避风港 沪农 ...